NewEdge Advisors LLC Buys 3,025 Shares of HCA Healthcare, Inc. $HCA

NewEdge Advisors LLC boosted its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 48.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,309 shares of the company’s stock after acquiring an additional 3,025 shares during the quarter. NewEdge Advisors LLC’s holdings in HCA Healthcare were worth $4,406,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in HCA. Palisade Asset Management LLC bought a new stake in HCA Healthcare during the third quarter valued at approximately $26,000. Ares Financial Consulting LLC bought a new stake in shares of HCA Healthcare during the 4th quarter valued at $31,000. Cedar Mountain Advisors LLC bought a new position in HCA Healthcare in the 1st quarter worth $33,000. JPL Wealth Management LLC bought a new stake in HCA Healthcare during the third quarter valued at about $33,000. Finally, MCF Advisors LLC lifted its position in shares of HCA Healthcare by 213.0% during the 4th quarter. MCF Advisors LLC now owns 72 shares of the company’s stock valued at $34,000 after buying an additional 49 shares in the last quarter. Hedge funds and other institutional investors own 62.73% of the company’s stock.

Analysts Set New Price Targets

HCA has been the topic of a number of recent analyst reports. Jefferies Financial Group set a $450.00 target price on shares of HCA Healthcare in a research note on Tuesday, July 14th. Cantor Fitzgerald decreased their price objective on shares of HCA Healthcare from $588.00 to $525.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 7th. Wells Fargo & Company increased their price target on HCA Healthcare from $369.00 to $381.00 and gave the stock an “equal weight” rating in a research note on Monday, August 3rd. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of HCA Healthcare in a research note on Wednesday, July 15th. Finally, JPMorgan Chase & Co. decreased their target price on HCA Healthcare from $535.00 to $490.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 19th. Fourteen equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $465.59.

Key Headlines Impacting HCA Healthcare

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: HCA’s Tennessee hospital appointed a new chief executive, providing a leadership update that could support local operations, although the move is unlikely to materially affect the broader company in the near term. HCA Tennessee hospital taps CEO
• Neutral Sentiment: HCA’s former CFO discussed the importance of partnerships in healthcare. The comments may reinforce the strategic value of collaboration and care-network development, but they do not indicate a new financial initiative or immediate change to HCA’s earnings outlook. HCA Healthcare’s former CFO on the role of partnerships in health
• Negative Sentiment: Healthcare workers at HCA hospitals are pushing for higher pay and increased staffing. Potential wage increases, labor-related disruptions and continued staffing shortages could raise operating costs and pressure margins, while criticism over staffing may create reputational risks. HCA workers push for higher pay and more staffing amid billions in profits
• Negative Sentiment: Zacks Research lowered EPS forecasts for HCA’s third and fourth quarters of 2026, multiple quarters in 2027 and the first two quarters of 2028. Its FY2027 estimate fell to $31.27 from $32.32, while the Q3 2026 forecast declined to $6.79 from $7.23. These broad estimate cuts are likely the main catalyst for the stock’s decrease because they imply softer-than-previously-expected earnings momentum.

HCA Healthcare Trading Down 0.6%

NYSE HCA opened at $411.55 on Wednesday. The stock has a market cap of $89.10 billion, a PE ratio of 13.78, a PEG ratio of 1.44 and a beta of 1.10. HCA Healthcare, Inc. has a 12 month low of $353.99 and a 12 month high of $556.52. The company’s 50-day moving average price is $390.75 and its 200-day moving average price is $447.87.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings results on Friday, July 24th. The company reported $7.59 earnings per share for the quarter, beating the consensus estimate of $7.56 by $0.03. The firm had revenue of $20.23 billion during the quarter, compared to the consensus estimate of $19.76 billion. HCA Healthcare had a net margin of 8.77% and a negative return on equity of 244.79%. The company’s revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.84 earnings per share. As a group, sell-side analysts forecast that HCA Healthcare, Inc. will post 29.45 earnings per share for the current year.

HCA Healthcare Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 16th will be issued a $0.78 dividend. This represents a $3.12 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Wednesday, September 16th. HCA Healthcare’s payout ratio is presently 10.45%.

HCA Healthcare Company Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.